की कीमत क्या है Neumora Therapeutics, Inc. Common Stock (NMRA)

का मूल्य Neumora Therapeutics, Inc. Common Stock (NMRA) है $1.33

का बाजार पूंजीकरण क्या है Neumora Therapeutics, Inc. Common Stock (NMRA)

का बाजार पूंजीकरण Neumora Therapeutics, Inc. Common Stock (NMRA) है $246.43M

Neumora Therapeutics, Inc. Common Stock (NMRA) P/B अनुपात

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

वर्ष	P/B अनुपात	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

P/B अनुपात

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	P/B अनुपात	P/B अनुपात में अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	6.828	-	US
Argenx SE ARGX.US	7.5116	-	NL
Moderna, Inc. MRNA.US	8.2199	-	US
CSL Limited CSL.AX	3.9942	-	AU
Lonza Group AG LONN.SW	-	-	CH

कंपनी

P/B अनुपात

P/B अनुपात में अंतर

देश